CN116249529A - 喹唑啉衍生物及其在医药上的应用 - Google Patents

喹唑啉衍生物及其在医药上的应用 Download PDF

Info

Publication number
CN116249529A
CN116249529A CN202180063168.5A CN202180063168A CN116249529A CN 116249529 A CN116249529 A CN 116249529A CN 202180063168 A CN202180063168 A CN 202180063168A CN 116249529 A CN116249529 A CN 116249529A
Authority
CN
China
Prior art keywords
compound
quinazolin
ethyl
pharmaceutically acceptable
meso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180063168.5A
Other languages
English (en)
Chinese (zh)
Inventor
周锡兵
魏用刚
张靖
楚洪柱
孙毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Baiyu Pharmaceutical Co Ltd
Original Assignee
Chengdu Baiyu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Baiyu Pharmaceutical Co Ltd filed Critical Chengdu Baiyu Pharmaceutical Co Ltd
Publication of CN116249529A publication Critical patent/CN116249529A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180063168.5A 2020-12-30 2021-12-27 喹唑啉衍生物及其在医药上的应用 Pending CN116249529A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202011600267 2020-12-30
CN2020116002676 2020-12-30
CN202110150212 2021-02-04
CN2021101502128 2021-02-04
CN202110144993X 2021-02-05
CN202110144993 2021-02-05
CN202110398907 2021-04-14
CN2021103989078 2021-04-14
CN2021112386652 2021-10-29
CN202111238665 2021-10-29
PCT/CN2021/141677 WO2022143533A1 (fr) 2020-12-30 2021-12-27 Dérivé de quinazoline et son utilisation en médecine

Publications (1)

Publication Number Publication Date
CN116249529A true CN116249529A (zh) 2023-06-09

Family

ID=82260204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180063168.5A Pending CN116249529A (zh) 2020-12-30 2021-12-27 喹唑啉衍生物及其在医药上的应用

Country Status (2)

Country Link
CN (1) CN116249529A (fr)
WO (1) WO2022143533A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258057A1 (fr) * 2021-06-11 2022-12-15 Jingrui Biopharma Co., Ltd. Composés en tant qu'agents anticancéreux

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9520822D0 (en) * 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
US7078409B2 (en) * 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP3878850A1 (fr) * 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1
TW202144338A (zh) * 2020-04-08 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用

Also Published As

Publication number Publication date
WO2022143533A1 (fr) 2022-07-07

Similar Documents

Publication Publication Date Title
EP3698782B1 (fr) Composés carbamates pour utilisation en thérapie
ES2426951T3 (es) Imidazopiridazinacarbonitrilos útiles como inhibidores de quinasa
JP6139789B2 (ja) 縮合複素環化合物、その調製方法、医薬組成物及びその使用
US8461170B2 (en) Chemical compounds
JP7428806B2 (ja) プリン誘導体および医薬におけるその使用
WO2020190774A1 (fr) Nouveaux inhibiteurs à petites molécules de facteurs de transcription tead
CN115232121B (zh) 吡啶衍生物及其在医药上的应用
KR102558308B1 (ko) 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
CN113544131B (zh) 吡咯并杂环类衍生物、其制备方法及其在医药上的应用
EP3481824B1 (fr) Dérivés de 2-phénylimidazo[4,5-b]pyridine-7-amine pouvant être utilisés comme inhibiteurs de l'activité de la tyrosine kinase ror1 de mammifères
CN118055933A (zh) 选择性parp1抑制剂及其应用
WO2020172258A1 (fr) Modulateurs de la protéine proto-oncogène de la famille myc
EP3283487B1 (fr) Pyrimidopyrimidinones et leurs utilisation comme modulateurs du receptor nmda
CN116249529A (zh) 喹唑啉衍生物及其在医药上的应用
JP2016531947A (ja) 配座固定されたＰＩ３Ｋ及びｍＴＯＲ阻害剤
BR112020026337A2 (pt) Compostos tricíclicos
WO2017012502A1 (fr) Composés de quinazoline substitués, ainsi que préparation et utilisations de ceux-ci
CA2934257C (fr) Derive d'imidazoline-5-one utile en tant qu'inhibiteur de fas pour le traitement du cancer
CN116157396A (zh) 哒嗪酮衍生物及其在医药上的应用
CN114539286B (zh) 哌嗪衍生物及其在医药上的应用
CN112851587A (zh) 一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
CN114621244B (zh) 吡啶衍生物及其在医药上的应用
WO2022152313A1 (fr) Dérivé de pyrimidine et son application pharmaceutique
AU2018212151B2 (en) Imidazopyridazine compound
CN115960106B (zh) 线粒体rna聚合酶抑制剂及其衍生物、药物组合物和医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination